Role of the Hancock "stabilized glutaraldehyde process" bioprosthesis in the management of mitral valve disease.
The low mortality of isolated mitral valve (MV) replacement permits attention to be focused on those valve-related factors which affect the quality of life after operation. Comparison of a number of MV prostheses indicates that all perform satisfactorily from the hemodynamic standpoint. An asset of the "stabilized glutaraldehyde process" (SGP) Hancock bioprosthesis (H-B) is the significantly lower incidence of thromboembolism encountered in patients who have not been permanently anticoagulated. While additional time is required before meaningful durability comparisons can be made, the absence of valve failure and the low incidence of tissue dysfunction in H-B over 6 1/2 years is encouraging. Although the ideal device for replacing the MV is not yet available, the Hancock SGP bioprostheses represent the best compromise of available choices.
D000447:Aldehydes; D001777:Blood Coagulation; D001794:Blood Pressure; D005069:Evaluation Studies as Topic; D005976:Glutaral; D006339:Heart Rate; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D008943:Mitral Valve / Q000166:cytology / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000601:surgery*; D008946:Mitral Valve Stenosis / Q000601:surgery*; D013923:Thromboembolism / Q000209:etiology; D013997:Time Factors
D000447:Aldehydes; D005976:Glutaral